---
title: "COMPASS Pathways plc (CMPS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CMPS.US.md"
symbol: "CMPS.US"
name: "COMPASS Pathways plc"
industry: "Biotechnology"
datetime: "2026-05-21T13:43:45.548Z"
locales:
  - [en](https://longbridge.com/en/quote/CMPS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CMPS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CMPS.US.md)
---

# COMPASS Pathways plc (CMPS.US)

## Company Overview

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [compasspathways.com](https://compasspathways.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.20 | 424 | - | - | - |
| PB | 4.49 | 309 | 17.30 | 3.85 | 2.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 71% |
| Overweight | 3 | 21% |
| Hold | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.95 |
| Highest Target | 70.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CMPS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CMPS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CMPS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CMPS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**